glp-1 drug shortages How drugs are used FDA's compounded GLP-1 limits will

In the meta-analysis, the different follow-up periods across studies were included, which could increase the chance of heterogeneity

A study shows that GLP-1 receptor agonists show a notably reduced incidence of primary open-angle glaucoma (POAG), ocular hypertension, and the requirement for first-line glaucoma treatments compared to metformin in individuals with type 2 diabetes (80)

Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, et al

Scientific Reference 2: Wilding et al., New England Journal of Medicine (2021) 2

The treatment plan depends on clinical goals: sleep/anxiety, vasomotor symptoms, libido, bone health, and more

Meanwhile, individuals who took a high-potency GLP-1 drug approved for obesity - such as semaglutide - had greater persistence at 14% three years after initiating therapy